{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:13:06Z","timestamp":1790835186807,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 DK072482"],"award-info":[{"award-number":["P30 DK072482"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 DK 089507"],"award-info":[{"award-number":["P30 DK 089507"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01HL128192"],"award-info":[{"award-number":["P01HL128192"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35 HL135816"],"award-info":[{"award-number":["R35 HL135816"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR002319"],"award-info":[{"award-number":["UL1 TR002319"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR002548"],"award-info":[{"award-number":["UL1TR002548"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR003096"],"award-info":[{"award-number":["UL1 TR003096"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002535"],"award-info":[{"award-number":["UL1 TR002535"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jcf.2022.07.008","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T08:24:28Z","timestamp":1658391868000},"page":"79-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study"],"prefix":"10.1016","volume":"22","author":[{"given":"N","family":"Mayer-Hamblett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7507-9337","authenticated-orcid":false,"given":"ET","family":"Zemanick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9779-2571","authenticated-orcid":false,"given":"K","family":"Odem-Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5727-8164","authenticated-orcid":false,"given":"D","family":"VanDevanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1630-6018","authenticated-orcid":false,"given":"M","family":"Warden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-0133","authenticated-orcid":false,"given":"SM","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0557-7277","authenticated-orcid":false,"given":"MW","family":"Konstan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"for-the-CHEC-SC-Study-Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2022.07.008_bib0001","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1056\/NEJMra1300109","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.07.008_bib0002","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation","volume":"181S","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2022.07.008_bib0003","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications","volume":"201","author":"Mall","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.07.008_bib0004","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.07.008_bib0005","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.07.008_bib0006","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2022.07.008_bib0007","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.07.008_bib0008","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.07.008_bib0009","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2013.09.007","article-title":"Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data","volume":"13","author":"Accurso","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.07.008_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11080729","article-title":"Sweat chloride testing and nasal potential difference (NPD) are primary outcome parameters in treatment with cystic fibrosis transmembrane conductance regulator (CFTR) modulators","volume":"11","author":"Sermet-Gaudelus","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.jcf.2022.07.008_bib0011","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1164\/rccm.201909-1845LE","article-title":"Females with cystic fibrosis demonstrate a differential response profile to ivacaftor compared with males","volume":"201","author":"Secunda","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.07.008_bib0012","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.jcf.2020.05.004","article-title":"Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor\/ivacaftor compared to males","volume":"20","author":"Aalbers","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.07.008_bib0013","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.07.008_bib0014","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2022.07.008_bib0015","unstructured":"CFTR CaFTo. Clinical and Functional Translation of CFTR 2011 [cited 2022. Available from: https:\/\/cftr2.org\/mutations_history."},{"key":"10.1016\/j.jcf.2022.07.008_bib0016","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jcf.2019.06.010","article-title":"Theranostics by testing CFTR modulators in patient-derived materials: the current status and a proposal for subjects with rare CFTR mutations","volume":"18","author":"Amaral","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.07.008_bib0017","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1164\/rccm.201901-0145OC","article-title":"Correlating cystic fibrosis transmembrane conductance regulator function with clinical features to inform precision treatment of cystic fibrosis","volume":"199","author":"McCague","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.07.008_bib0018","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jcf.2021.01.011","article-title":"Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: rationale and design of the CHEC-SC study","volume":"20","author":"Zemanick","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.07.008_bib0019","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","article-title":"Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function","volume":"13","author":"Van Goor","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.07.008_bib0020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jcf.2011.12.005","article-title":"Ivacaftor potentiation of multiple CFTR channels with gating mutations","volume":"11","author":"Yu","year":"2012","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.07.008_bib0021","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121159","article-title":"Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators","volume":"3","author":"Han","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcf.2022.07.008_bib0022","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.07.008_bib0023","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2022.07.008_bib0024","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/MCP.0000000000000521","article-title":"Theratyping in cystic fibrosis","volume":"24","author":"Crawford","year":"2018","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jcf.2022.07.008_bib0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.07.008_bib0026","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcf.2016.10.002","article-title":"Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor","volume":"16","author":"Fidler","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.07.008_bib0027","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.07.008_bib0028","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1378\/chest.12-1430","article-title":"Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience","volume":"143","author":"Durmowicz","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2022.07.008_bib0029","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1513\/AnnalsATS.202002-144OC","article-title":"Clinical effectiveness of lumacaftor\/ivacaftor in patients with cystic fibrosis homozygous for F508del-CFTR. A clinical trial","volume":"18","author":"Sagel","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2022.07.008_bib0030","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1164\/rccm.201710-2046LE","article-title":"Ivacaftor-treated patients with cystic fibrosis derive long-term benefit despite no short-term clinical improvement","volume":"197","author":"Heltshe","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.07.008_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2022.02.003","article-title":"A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor\/ivacaftor in children >\/= 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant","author":"Sawicki","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.07.008_bib0032","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: interim results of an open-label phase 3 clinical trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.07.008_bib0033","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s41030-020-00129-2","article-title":"Long-term ivacaftor in people aged 6 years and older with cystic fibrosis with ivacaftor-responsive mutations","volume":"6","author":"Pilewski","year":"2020","journal-title":"Pulm Ther"},{"key":"10.1016\/j.jcf.2022.07.008_bib0034","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jcf.2020.11.008","article-title":"Investigators GO-e. Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation","volume":"20","author":"Guimbellot","year":"2021","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322006257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322006257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:47:14Z","timestamp":1761601634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199322006257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1569199322006257"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2022.07.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2022.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}